Biomed Lublin treatment for covid passes three pronged clinical trial: Convalescent plasma treatment

“We are completing the collection of plasma from Covid-19-recovered donors to produce the first batch of our drug. Depending on the titre we will produce 2,000-4,000 ampules for clinical trials,” explains Mr Piróg. “Production should start by mid-August and the product shall be delivered to hospitals running trials by the end of September.”

Already, the drug is gaining traction, and contracts signed with both Germany and Turkey allow the company to further improve results in co-ordinance with sales.

This success from Biomed Lublin follows the company’s 75-year history of dealing with epidemics and pandemics.

“We produced dozens of different vaccines, serums, and immunoglobulins to save lives and make people feel safe for several generations,” says Mr Piróg. One of the company’s most notable successes has been the BCG-10 vaccine against tuberculosis, as well as playing a fundamental role in the development of treatments against diseases such as rabies, typhoid, and tuberculous.

This strong history meant that even before the pandemic arose, Biomed Lublin, previously known as the Laboratory for Production of Vaccines Against Typhus, had the required technology to produce a convalescent plasma treatment, again speeding up the process.